Gastroparesis Trial, Recruiting (NCT04696159)

Gastroparesis Trial, Recruiting NCT04696159 Sponsor: Matthew Allemang Condition: Gastroparesis

Printed from Voxsanity (voxsanity.com.au) — NCT04696159 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Gastroparesis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years of age or older
You have been diagnosed with gastroparesis (a condition where the stomach empties food more slowly than normal) and your average blood sugar control level (HbA1c) has been above 7.5% over the past 3 months
You have had a confirmed diagnosis of delayed stomach emptying through a specific test (either a wireless capsule study or a nuclear stomach emptying scan), with no sign of a blockage in the stomach
You are able and willing to complete all parts of the study as required

Who may not be able to join:

You are under 18 years of age
Your average blood sugar control level (HbA1c) has been below 7.5% over the past 3 months
You are unable or unwilling to complete all of the study requirements
You are unable or unwilling to wear a continuous glucose monitor (CGM) sensor, which is a small device worn on the skin to track blood sugar levels
You currently use an insulin pump (a device that automatically delivers insulin)
You already use a continuous glucose monitor (CGM)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mathew Allemang, MD, The Cleveland Clinic

Phone: 216-445-0953

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04696159

Sponsor: Matthew Allemang

Phase: Not Applicable

Status: Recruiting

Condition: Gastroparesis

Trial contact: 216-445-0953

More information: https://clinicaltrials.gov/study/NCT04696159

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years of age or older
You have been diagnosed with gastroparesis (a condition where the stomach empties food more slowly than normal) and your average blood sugar control level (HbA1c) has been above 7.5% over the past 3 months
You have had a confirmed diagnosis of delayed stomach emptying through a specific test (either a wireless capsule study or a nuclear stomach emptying scan), with no sign of a blockage in the stomach
You are able and willing to complete all parts of the study as required

Who may not be able to join:

You are under 18 years of age
Your average blood sugar control level (HbA1c) has been below 7.5% over the past 3 months
You are unable or unwilling to complete all of the study requirements
You are unable or unwilling to wear a continuous glucose monitor (CGM) sensor, which is a small device worn on the skin to track blood sugar levels
You currently use an insulin pump (a device that automatically delivers insulin)
You already use a continuous glucose monitor (CGM)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Matthew Allemang

Registry

ClinicalTrials.gov

Start date

4 January 2023

Est. completion

1 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from Baseline in Hemoglobin A1C levels; Change from Baseline in Glucose Levels measured by Continuous Glucose Monitor

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov